Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

Published:2019-09-24 Issue:1 Volume:13 Page:41-46
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Vishwanathan Karthick¹,Cantarini Mireille²,So Karen³,Masson Eric¹,Fetterolf Jennifer⁴,Ramalingam Suresh S.⁵,Harvey R. Donald⁵

Affiliation:

1. Clinical Pharmacology and Safety Sciences Research & Development AstraZeneca Waltham Massachusetts USA

2. Oncology Research & Development AstraZeneca Macclesfield UK

3. Oncology Research & Development AstraZeneca Cambridge UK

4. BioPharmaceuticals Research & Development AstraZeneca Gaithersburg Maryland USA

5. Winship Cancer Institute of Emory University Atlanta Georgia USA

Funder

AstraZeneca

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12688

Reference25 articles.

1. Metabolism‐related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations

2. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects;Lynch T.;Am. Fam. Physician,2007

3. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

4. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role;Pharmaceuticals;2022-05-10

2. Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors;Pharmaceutics;2020-09-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3